期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 193, 期 1, 页码 93-100出版社
WILEY
DOI: 10.1111/bjh.17131
关键词
health‐ related quality of life; lenalidomide; multiple myeloma; real‐ world evidence
类别
资金
- Bristol Myers Squibb
RVd treatment significantly improved HRQoL compared to Vd/VMP in newly diagnosed multiple myeloma patients, with similar rates of serious adverse events across all groups. RVd treatment maintained HRQoL in this real-world, largely community-based population of NDMM patients.
Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect(R) MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据